{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:08:39Z","timestamp":1788732519924,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41440-026-02725-2","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:34:21Z","timestamp":1783931661000},"page":"2548-2560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breakthrough drugs in the treatment of hypertension-related disease"],"prefix":"10.1038","volume":"49","author":[{"given":"Satoshi","family":"Hoshide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2725_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/ggi.14565","volume":"23","author":"M Mogi","year":"2023","unstructured":"Mogi M, Liu S, Watanabe R, Imai M, Yano A, Ikegawa Y, et al. Perspectives on frailty as a total life-course disease with consideration of the fetal environment. Geriatr Gerontol Int. 2023;23:263\u20139.","journal-title":"Geriatr Gerontol Int"},{"key":"2725_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41440-024-01642-6","volume":"47","author":"M Mogi","year":"2024","unstructured":"Mogi M, Ikegawa Y, Haga S, Hoshide S, Kario K. Hypertension facilitates age-related diseases. ~ Is hypertension associated with a wide variety of diseases?~. Hypertens Res. 2024;47:1246\u201359.","journal-title":"Hypertens Res"},{"key":"2725_CR3","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394:639\u201351."},{"key":"2725_CR4","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/s41440-025-02331-8","volume":"48","author":"Y Ohya","year":"2025","unstructured":"Ohya Y, Sakima A, Arima H, Fukami A, Furuhashi M, Ishida M, et al. Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res. 2025;48:2500\u201311.","journal-title":"Hypertens Res"},{"key":"2725_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","volume":"124","author":"M Burnier","year":"2019","unstructured":"Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124:1124\u201340.","journal-title":"Circ Res"},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.70063","volume":"182","author":"F Pu","year":"2025","unstructured":"Pu F, Liu Y, Ahmed FZ, Wang X, Green D, Zhang H. Advancing antihypertensive drug development. Br J Pharm. 2025;182:3389\u2013410.","journal-title":"Br J Pharm"},{"key":"2725_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1124\/dmd.121.000428","volume":"50","author":"R McDougall","year":"2022","unstructured":"McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. The Nonclinical Disposition And Pharmacokinetic\/pharmacodynamic Properties of N-Acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab disposition: Biol Fate Chem. 2022;50:781\u201397.","journal-title":"Drug Metab disposition: Biol Fate Chem"},{"key":"2725_CR8","doi-asserted-by":"crossref","unstructured":"Menezes Junior ADS, Nogueira THM, de Lima KBA, de Oliveira HL, Botelho SM. Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review. J Pers Med 2024;15:3.","DOI":"10.3390\/jpm15010003"},{"key":"2725_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","volume":"6","author":"ES Morgan","year":"2021","unstructured":"Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, et al. Antisense inhibition of Angiotensinogen with IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci. 2021;6:485\u201396.","journal-title":"JACC Basic Transl Sci"},{"key":"2725_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","volume":"73","author":"E Uijl","year":"2019","unstructured":"Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and sustained antihypertensive effect of small interfering RNA targeting liver Angiotensinogen. Hypertension. 2019;73:1249\u201357.","journal-title":"Hypertension"},{"key":"2725_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","volume":"334","author":"AS Desai","year":"2025","unstructured":"Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, et al. Add-on treatment With Zilebesiran for inadequately controlled hypertension: The KARDIA-2 randomized clinical trial. Jama. 2025;334:46\u201355.","journal-title":"Jama"},{"key":"2725_CR13","unstructured":"KARDIA-3 trial examines blood-pressure lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk. European Society of Cardiology, Press Release, 30 Aug, 2025. https:\/\/www.escardio.org\/news\/press\/press-releases\/KARDIA-3-trial-examines-blood-pressure-lowering-effects-of-zilebesiran-in-hypertensive-patients-at-high-cardiovascular-risk\/. Accessed 20 April 2026."},{"key":"2725_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nbt.4136","volume":"36","author":"I Zlatev","year":"2018","unstructured":"Zlatev I, Castoreno A, Brown CR, Qin J, Waldron S, Schlegel MK, et al. Reversal of siRNA-mediated gene silencing in vivo. Nat Biotechnol. 2018;36:509\u201311.","journal-title":"Nat Biotechnol"},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.124.22878","volume":"81","author":"D Ye","year":"2024","unstructured":"Ye D, Cruz-L\u00f3pez EO, Veghel RV, Garrelds IM, Kasper A, Wassarman K, et al. Counteracting angiotensinogen small-interfering rna-mediated antihypertensive effects with REVERSIR. Hypertension. 2024;81:1491\u20139.","journal-title":"Hypertension"},{"key":"2725_CR16","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.2147\/IJN.S436038","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L. A comprehensive review of Small Interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy. Int J Nanomed. 2023;18:7605\u201335.","journal-title":"Int J Nanomed"},{"key":"2725_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41440-020-0508-z","volume":"43","author":"T Hisamatsu","year":"2020","unstructured":"Hisamatsu T, Segawa H, Kadota A, Ohkubo T, Arima H, Miura K. Epidemiology of hypertension in Japan: beyond the new 2019 Japanese guidelines. Hypertens Res. 2020;43:1344\u201351.","journal-title":"Hypertens Res"},{"key":"2725_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14938","volume":"27","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, et al. Efficacy and safety of Sacubitril\/Valsartan Versus Amlodipine in Japanese patients with essential hypertension: a randomized, multicenter, open-label, noninferiority study (PARASOL Study). J Clin Hypertens. 2025;27:e14938.","journal-title":"J Clin Hypertens"},{"key":"2725_CR19","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2725_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14947","volume":"27","author":"K Kario","year":"2025","unstructured":"Kario K, Katsuya T, Shimosawa T, Taguchi T, Tanabe A, Ohishi M. Rationale and design of a randomized, open-label, parallel-group study of Esaxerenone therapy (ESCORT-HT). J Clin Hypertens. 2025;27:e14947.","journal-title":"J Clin Hypertens"},{"key":"2725_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255\u201366.","journal-title":"Lancet"},{"key":"2725_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"2725_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540\u201350.","journal-title":"Lancet"},{"key":"2725_CR24","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791\u2013800.","journal-title":"Kidney Int"},{"key":"2725_CR25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med"},{"key":"2725_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diab Endocrinol. 2014;2:944\u201353.","journal-title":"Lancet Diab Endocrinol"},{"key":"2725_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","volume":"42","author":"M Nishimoto","year":"2019","unstructured":"Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertension Res. 2019;42:514\u201321.","journal-title":"Hypertension Res"},{"key":"2725_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic kidney disease outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2725_CR29","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/ndt\/gfad098","volume":"38","author":"H Nishio","year":"2023","unstructured":"Nishio H, Ishii A, Yamada H, Mori KP, Kato Y, Ohno S, et al. Sacubitril\/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. Nephrol Dialysis Transpl. 2023;38:2517\u201327.","journal-title":"Nephrol Dialysis Transpl"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"2725_CR31","first-page":"709","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Random Aldactone Eval Study Investig N Engl J Med. 1999;341:709\u201317.","journal-title":"Random Aldactone Eval Study Investig N Engl J Med"},{"key":"2725_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"2725_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404:1119\u201331.","journal-title":"Lancet"},{"key":"2725_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","volume":"406","author":"M Walsh","year":"2025","unstructured":"Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, et al. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet. 2025;406:695\u2013704.","journal-title":"Lancet"},{"key":"2725_CR35","doi-asserted-by":"publisher","first-page":"e2429237","DOI":"10.1001\/jamanetworkopen.2024.29237","volume":"7","author":"D Le","year":"2024","unstructured":"Le D, Grams ME, Coresh J, Shin JI. Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Netw Open. 2024;7:e2429237.","journal-title":"JAMA Netw Open"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","volume":"217","author":"MH Bassett","year":"2004","unstructured":"Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol. 2004;217:67\u201374.","journal-title":"Mol Cell Endocrinol"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025;392:1813\u201323.","journal-title":"N Engl J Med"},{"key":"2725_CR38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393:1363\u201374.","journal-title":"N Engl J Med"},{"key":"2725_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/HJH.0000000000001275","volume":"35","author":"P Kumarathurai","year":"2017","unstructured":"Kumarathurai P, Anholm C, Fabricius-Bjerre A, Nielsen OW, Kristiansen O, Madsbad S, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. J Hypertension. 2017;35:1070\u20138.","journal-title":"J Hypertension"},{"key":"2725_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MBP.0000000000000537","volume":"26","author":"D Patoulias","year":"2021","unstructured":"Patoulias D, Papadopoulos C, Siskos F, Stavropoulos K, Doumas M. The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. Blood Press Monit. 2021;26:284\u20137.","journal-title":"Blood Press Monit"},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","volume":"81","author":"JA de Lemos","year":"2024","unstructured":"de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index \u226527 kg\/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 2024;81:e41\u2013e43.","journal-title":"Hypertension"},{"key":"2725_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on chronic kidney disease in patients with Type 2 diabetes. N Engl J Med. 2024;391:109\u201321.","journal-title":"N Engl J Med"},{"key":"2725_CR43","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly Semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous Semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Jama. 2021;325:1403\u201313.","journal-title":"Jama"},{"key":"2725_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384.","journal-title":"N Engl J Med"},{"key":"2725_CR47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2019;381:841\u201351.","journal-title":"N Engl J Med"},{"key":"2725_CR48","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958\u201371.","journal-title":"N Engl J Med"},{"key":"2725_CR49","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811\u201324.","journal-title":"Lancet"},{"key":"2725_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427\u201337.","journal-title":"N Engl J Med"},{"key":"2725_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"2725_CR52","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","volume":"45","author":"C Kennedy","year":"2024","unstructured":"Kennedy C, Hayes P, Cicero AFG, Dobner S, Le Roux CW, McEvoy JW, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. 2024;45:4124\u201334.","journal-title":"Eur Heart J"},{"key":"2725_CR53","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"AC Huby","year":"2015","unstructured":"Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone Leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132:2134\u201345.","journal-title":"Circulation"},{"key":"2725_CR54","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069\u201378.","journal-title":"Hypertension"},{"key":"2725_CR55","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JME-16-0025","volume":"57","author":"AN Dinh Cat","year":"2016","unstructured":"Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57:F7\u2013f21.","journal-title":"J Mol Endocrinol"},{"key":"2725_CR56","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s41440-023-01233-x","volume":"46","author":"I Usui","year":"2023","unstructured":"Usui I. Common metabolic features of hypertension and type 2 diabetes. Hypertens Res. 2023;46:1227\u201333.","journal-title":"Hypertens Res"},{"key":"2725_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","volume":"26","author":"S Sivalingam","year":"2024","unstructured":"Sivalingam S, Wasehuus VS, Rotbain Curovic V, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diab, Obes Metab. 2024;26:54\u201364.","journal-title":"Diab, Obes Metab"},{"key":"2725_CR58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscleros Thromb Vasc Biol. 2020;40:145\u201358.","journal-title":"Arterioscleros Thromb Vasc Biol"},{"key":"2725_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","volume":"671","author":"X Luo","year":"2019","unstructured":"Luo X, Hu Y, He S, Ye Q, Lv Z, Liu J, et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;671:203\u20139.","journal-title":"Arch Biochem Biophys"},{"key":"2725_CR60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","volume":"261","author":"T Jojima","year":"2017","unstructured":"Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2017;261:44\u201351.","journal-title":"Atherosclerosis"},{"key":"2725_CR61","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1210\/jc.2003-031403","volume":"89","author":"JP Gutzwiller","year":"2004","unstructured":"Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89:3055\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"2725_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49364-x","volume":"9","author":"K Katsurada","year":"2019","unstructured":"Katsurada K, Nakata M, Saito T, Zhang B, Maejima Y, Nandi SS, et al. Central Glucagon-like Peptide-1 receptor signaling via Brainstem Catecholamine neurons counteracts hypertension in spontaneously hypertensive rats. Sci Rep. 2019;9:12986.","journal-title":"Sci Rep"},{"key":"2725_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170174","volume":"125","author":"SM Heimb\u00fcrger","year":"2020","unstructured":"Heimb\u00fcrger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides. 2020;125:170174.","journal-title":"Peptides"},{"key":"2725_CR64","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","volume":"110","author":"HM Krumholz","year":"2024","unstructured":"Krumholz HM, de Lemos JA, Sattar N, Linetzky B, Sharma P, Mast CJ, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 2024;110:1165\u201371.","journal-title":"Heart"},{"key":"2725_CR65","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"2725_CR66","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diab Obes Metab. 2018;20:479\u201387.","journal-title":"Diab Obes Metab"},{"key":"2725_CR67","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","volume":"5","author":"LY Herat","year":"2020","unstructured":"Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, et al. SGLT2 inhibitor-induced Sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5:169\u201379.","journal-title":"JACC Basic Transl Sci"},{"key":"2725_CR68","doi-asserted-by":"publisher","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","volume":"327","author":"ACC Girardi","year":"2024","unstructured":"Girardi ACC, Polidoro JZ, Castro PC, Pio-Abreu A, Noronha IL, Drager LF. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions. Am J Physiol Cell Physiol. 2024;327:C525\u2013c544.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2725_CR69","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diab Obes Metab. 2015;17:1180\u201393.","journal-title":"Diab Obes Metab"},{"key":"2725_CR70","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"2725_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2725_CR72","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"2725_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"2725_CR74","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"K Kario","year":"2019","unstructured":"Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. Twenty-four-hour blood pressure-lowering effect of a sodium-glucose Cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA Study. Circulation. 2019;139:2089\u201397.","journal-title":"Circulation"},{"key":"2725_CR75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/hr.2016.193","volume":"40","author":"A Rahman","year":"2017","unstructured":"Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res. 2017;40:535\u201340.","journal-title":"Hypertens Res"},{"key":"2725_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diab Endocrinol. 2016;4:211\u201320.","journal-title":"Lancet Diab Endocrinol"},{"key":"2725_CR77","first-page":"236","volume":"56","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP, Oliveira AC, Vasques-Novoa F, Leite AR, Mendon\u00e7a L, Zannad F, et al. Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials. Am J Nephrol. 2025;56:236\u201342.","journal-title":"Am J Nephrol"},{"key":"2725_CR78","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/hr.2017.14","volume":"40","author":"T Yoshikawa","year":"2017","unstructured":"Yoshikawa T, Kishi T, Shinohara K, Takesue K, Shibata R, Sonoda N, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res. 2017;40:646\u201351.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02725-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:03:20Z","timestamp":1788732200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02725-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H has received honoraria for lectures from Novartis Pharma K.K. S.S. has received research funding from AstraZeneca K.K. and honoraria for lectures from Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., and Bayer Yakuhin, Ltd. T.K. has received honoraria for lectures from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., and Bayer Yakuhin, Ltd. The Department of Health Development and Medicine to which H.N. belongs is an endowed department supported by Anges, Daicel, and FunPep. In addition, H.N. serves as a scientific advisor to FunPep and holds stock in the company. A.N. has received honoraria for lectures from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd., Mochida Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corporation and received research funding (collaborative research) from Bayer Yakuhin, Ltd. I.U. has received honoraria for lectures from Daiichi Sankyo Co., Ltd. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}